Navigation Links
MiMedx Group Receives FDA Clearance to Market Its HydroFix™ Ortho Shield™ Device
Date:6/22/2011

MARIETTA, Ga., June 22, 2011 /PRNewswire/ -- MiMedx Group, Inc.  (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials including bioimplants processed from human amniotic membrane, announced today that the Company's proprietary device, HydroFix™ Ortho Shield™, has received 510(k) clearance. The Company also announced its receipt of two additional 510(k) clearances related to its HydroFix™ technology platform.

HydroFix™ Ortho Shield™ is indicated for the management and protection of tendon injuries in which there has been no substantial loss of tendon tissue. The patented HydroFix™ Ortho Shield™ is a biocompatible polyvinyl alcohol polymer (PVA) membrane that is indicated to minimize tissue attachment to the device in case of direct contact with the tissues. HydroFix™ Ortho Shield™ is a permanent protective sheet that minimizes soft tissue attachments to the device providing a protective environment for the repaired tendon to heal. The device is conformable, suturable, and biocompatible, providing surgeons with an easy to use option for tendon protection. The device also provides a smooth inner gliding surface for the tendon to move as part of normal motion.

Parker H. "Pete" Petit, Chairman and CEO, said, "We are pleased to receive these FDA clearances. Soft tissue attachments to repaired tendons can reduce the effectiveness of the repair and result in a reduced range of motion post surgery, so the HydroFix™ Ortho Shield™ meets an important clinical need. We are continuing to develop additional indications for this biomaterial in response to surgeon demand for a wide range of applications."

The two additional 510(K) clearances recently received from the FDA were for the Company's HydroFix™ Vaso Shield device. HydroFix™ Vaso Shield, indicated for use as a cover for vessels during anterior vertebral surgery, has now received clearance for an expanded range of sizes and for a higher temperature exposure limit.  Additionally, a large animal implantation study has demonstrated the ability of the device to minimize soft tissue attachments between the device and the surrounding soft tissue.

Bill Taylor, President and COO, stated, "Receiving these additional FDA clearances for our HydroFix™ technology is an important step in serving the needs and preferences of physicians that are utilizing our device in their surgical procedures. Surgeon feedback has included requests for new indications for use and new sizes for existing indications, and these new 510(k) clearances are a direct result of a portion of that surgeon feedback.  These FDA clearances are an integral part of our strategy of providing biomaterial solutions to unmet or underserved physician needs."

About the Company

MiMedx is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials including bioimplants manufactured from human amniotic membrane. The Company has an experienced team poised to capitalize on its science and technology to generate rapid sales growth and profitability.  Our tagline is "Innovations in Regenerative Biomaterials" because our biochemists, engineers, designers and physicians believe it is better to regenerate tissue when possible rather than replace traumatized, but otherwise healthy tissues and structures.  Our platform technologies, HydroFix™ and CollaFix™, and our newest platform technology, Purion® developed by our wholly-owned subsidiary, Surgical Biologics, have a vast number of potential applications in treating traumatized tissue and structures and MiMedx is focused on commercializing multiple applications for the Company's three technology platforms. In parallel, we are seeking strategic relationships, in selective categories, to more rapidly commercialize our technologies.  


'/>"/>
SOURCE MiMedx Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MiMedx Announces Launch of AmnioFix™ Nerve Wrap
2. MiMedx to Attend International Society for the Advancement of Spine Surgery Annual Meeting
3. MiMedx Group, Inc. Announces Release Date for First Quarter Results
4. MiMedx Completes Acquisition of Surgical Biologics
5. MiMedx Receives Additional CE Certification for Its HydroFix™ Technology
6. MiMedx Announces Agreement to Acquire Surgical Biologics
7. MiMedx Group, Inc. Announces Release Date for Second Quarter Results
8. MiMedx Group Announces Addition of Sales Director for Europe
9. MiMedx Group Announces CE Mark for the HydroFix(TM) Spine Shield
10. MiMedx Group Announces Launch of its Paradis Vaso Shield(TM) Device
11. Foundation Venture Capital Group Invests in Company Developing Plaque-Reducing Dental Hygiene Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... April 28, 2016  Marking its one year ... and ovarian cancer risk test, Color Genomics ... genes that highly impact the most common hereditary ... the Color Test analyzes hereditary cancer risks for ... uterine cancers. The Color Test is physician ordered ...
(Date:4/28/2016)... Dr. Vivek Ahuja , ... phen Schmidt Join the Growing ... solutions for life sciences, today announced key new leaders have joined ... to a growing business.  This will bolster the company,s safety business ... joined ArisGlobal in the position of Vice President - Safety. George ...
(Date:4/28/2016)... April 28, 2016 New ... 2016" is a report that provides an overview ... R&D pipelines by identifying new targets and MOAs ... Company Profiles discussed in this H1 2016 Osteoarthritis ... Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx NV, ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, ... animal line of probiotics, Petbiotics ™, as they fondly call them. As ... rescue groups networking for their non-profit organizations. Animal rescues across the nation face ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... billing and coding services, and Deyta Analytics, recently announced the recipients of the ... level of quality as measured from the caregiver’s point of view. The official ...
(Date:4/29/2016)... ... April 29, 2016 , ... Intellitec Solutions ... use of Microsoft Dynamics GP for one their long-term care clients. Working together ... Dynamics GP with key clinical management systems, and delivered a fully integrated accounting ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Society ... year, reproductive endocrinologists are required to report in vitro fertilization (IVF) ... dedicated to the practice of assisted reproductive technologies in the United States. ...
(Date:4/29/2016)... ... April 29, 2016 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... BC and AD, saying it is time to set the record straight. Traditionally, BC ... this simply cannot possibly be true and offers explanation. , “To start with, the ...
Breaking Medicine News(10 mins):